BPC-157 vs TB-500: The Research Comparison

BPC-157 is a synthetic 15-residue fragment, GEPPPGKPADDAGLV, of BPC, a roughly 40-residue protein identified in human gastric juice. It was characterized at the University of Zagreb from the early 1990s in the context of gastric cytoprotection.[1]

TB-500 is not thymosin β4. Thymosin β4 is a 43-residue, 4.9 kDa actin-sequestering protein present in most mammalian cells.[3] TB-500 as sold on the research market is normally the acetylated seven-residue fragment Ac-LKKTETQ from that protein's actin-binding region, about a quarter of its mass. Nearly all of the published literature is on the parent protein, not the fragment.

That asymmetry is the single most important thing in this comparison: the BPC-157 literature is about the molecule you are buying, and much of the TB-500 literature is not.

Amino Acid Sequence

Amino Acid Sequence

BPC-157. No single receptor has been established. The published mechanistic work centres on angiogenic signaling, on modulation of the nitric oxide system through the Src, Caveolin-1 and eNOS pathway,[5] and on effects in tendon fibroblast assays including outgrowth, survival and migration.[3 in the BPC-157 guide] The absence of an identified receptor is a real gap, not a detail.

Thymosin β4. The mechanism is unusually well defined for this category: it is the principal G-actin sequestering protein in mammalian cells, and the actin-binding function anchors everything downstream in wound, corneal and cardiac models.[3] Whether the seven-residue fragment reproduces that behaviour is a separate question the literature has largely not asked.

Neither compound has human efficacy trials. Below that ceiling they differ:

• ·BPC-157: volume, concentrated source. A large preclinical literature across gastrointestinal, tendon, wound and vascular models, much of it from one research group. Volume is a strength; concentration in one group is a limitation on how independently confirmed it is.
• ·Thymosin β4: quality, wrong molecule. Fewer but methodologically stronger papers, in higher-impact venues including Nature, and from independent groups.[4] The problem is that they are about the parent protein rather than the fragment in the vial.
• ·BPC-157 human work: an oral formulation (PL-14736) entered early clinical investigation for inflammatory bowel disease without a published pivotal dataset.
• ·Thymosin β4 human work: reached clinical investigation in dermal and corneal indications, with no approved indication.
• ·Neither has an established human dose, a human safety record of meaningful size, or authorization from Health Canada.

• ·Molecular size. BPC-157 is around 1419.5 Da; TB-500 is around 1030 Da. Both are straightforward syntheses, so a low purity figure on either points at a supplier problem rather than a difficult target.
• ·Naming risk. TB-500 carries a real risk of buying the wrong molecule, because "TB-500" and "thymosin β4" are used interchangeably in marketing and are not the same compound. A measured mass on the certificate settles it. BPC-157 has a smaller version of this problem in acetate against arginate salt forms, which are the same peptide.
• ·Regulatory position. Both were among the six peptides an FDA advisory committee voted in July 2026 to recommend for the Section 503A compounding bulks list, in each case against FDA staff's recommendation and by an 8-6 margin with one abstention. The votes are non-binding, no final determination has been issued, and neither appears in 21 CFR 216.23. Neither is authorized in Canada.
• ·Anti-doping. TB-500 and thymosin β4 appear on the World Anti-Doping Agency Prohibited List under growth factors affecting muscle, tendon or ligament. Researchers working with athletes ask about this often enough to state it.

The same three checks apply to both: MS identity against the expected mass, HPLC purity, and measured content against the labelled amount. For TB-500 the identity line does extra work, because it is the only thing that distinguishes the seven-residue fragment from anything else a supplier might have put in the vial.

Certificates for both compounds are published before sale and verifiable on the testing laboratory's own database.

Published Certificate

Select strength

10mg12mg20mg

Batch

BPC-CA-26F-10

Purity (HPLC)

99.765%

Measured content

10.98 mglabelled 10 mg

Laboratory

Janoshik

Verify on the lab’s own databaseAll published certificates

Published Certificate

Batch

TB5-CA-26F-10

Purity (HPLC)

99.182%

Measured content

11.52 mglabelled 10 mg

Laboratory

Janoshik

Verify on the lab’s own databaseAll published certificates

If the research question is about the compound in the vial, BPC-157 has the better-matched literature: the published work is on the same 15-residue molecule you are buying. If the research question is about actin sequestration and the parent protein biology, the honest answer is that the seven-residue fragment is a proxy for a molecule the literature studied, and that gap should be stated in the methods rather than assumed away.

Both are stocked, both have published certificates, and both are supplied strictly as research materials.

Available at Eppix Labs

Buy BPC-157 Canada | 10mg & 20mg Vials

10mg · 12mg · 20mg

Every batch tested by an independent laboratory, with the certificate published before sale.

From $50.00 CADIn stock

Available at Eppix Labs

Buy TB-500 Canada | Thymosin Beta-4 10mg

10mg

Every batch tested by an independent laboratory, with the certificate published before sale.

From $65.00 CADIn stock